Advantages of Concurrently Investigating Gene Therapies in Dogs and Humans

Video

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.

“From a perspective of gene expression, there's nothing to keep your expression profiles the same once you pass the age when you would typically procreate... there's no evolutionary pressure to keep things regulated. We're hoping that with the tools available today, we can piece something together to effectively reverse events that have occurred over your lifetime.”

Rejuvenate Bio is focused on treating age-related diseases, with an ultimate goal of reversing aging. To this end, they are targeting 3 genes associated with longevity: FGF21, αKlotho, and TGFβ1 in both dogs and humans and developing gene therapies in both populations.

A single dose of Rejuvenate’s gene therapies were able to treat, and in some cases even reverse, a set of age-related diseases in mouse models, including obesity, type 2 diabetes, heart failure, and renal failure.

GeneTherapyLive spoke with Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, to learn more about the advantages of investigating the same gene therapies in both dogs and humans in manufacturing and data collection. He also discussed the company’s future plans and research to further their ultimate goal of reversing aging.

REFERENCE
Davidsohn N, Pezone M, Vernet A, et al. A single combination gene therapy treats multiple age-related diseases. Proc. Natl. Acad. Sci. USA. Nov 2019, 116 (47) 23505-23511. doi: 10.1073/pnas.1910073116
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Related Content
© 2025 MJH Life Sciences

All rights reserved.